JFXL2
3 years ago
I'm new to this board and was introduced to this stock via another article, since I own Tilray (TLRY). I noticed there is not MOD on this board and the intro is kind of bland. In any event. Here is my contribution to everyone GLTA.
Cheers FX
The Miracle Compound Tackling A Trillion Dollar Crisis
8:00 am ET May 17, 2021 (PR Newswire) Print
Today, the world seeing the beginning of the next great biotech boom... and it has nothing to do with COVID-19. Thanks to new laws sweeping the United States, there might be a groundbreaking new opportunity building for companies like Havn Life (HAVN; HAVLF). Mentioned in today's commentary includes: Tilray, Inc. (NASDAQ: TLRY), Cronos Group Inc. (NASDAQ: CRON), Aurora Cannabis Inc. (NYSE: ACB), Canopy Growth Corporation (NASDAQ: CGC).
That's because researchers are finally re-thinking how we deal with mental health. According to Reuters, mental health disorders is projected to be costing the world $16 trillion in the 20 year period from 2010 to 2030. And at the moment, we're left with hundreds of flawed solutions.
That's the reason big-time investors like PayPal co-founder Peter Thiel, Shark Tank star Kevin O'Leary, and pot stock dynamo Bruce Linton are said to be investing money into the psychedelics space. And they are not alone.
Even some of the biggest pharmaceutical companies like Johnson & Johnson and $195 billion giant Abbvie are moving into this burgeoning market. At the same time, world-class institutions are racing ahead with groundbreaking research into the potential benefits of psychedelics.
That includes respected medical organizations like Johns Hopkins University, University of Toronto, Imperial College, and King's College. And one little-known biotech company could be set to take this space by storm. Havn Life is aiming to provide a reliable source of psilocybin for the hundreds of studies that are being carried out in this burgeoning industry.
Supplying the Anticipated Boom
Havn Life (HAVN; HAVLF) has developed a plan that could help make them part of the backbone of this growing industry. By delivering high-quality, naturally-derived psilocybin directly to researchers making these breakthroughs, they could serve a critical role. Being a leading supplier could also mean another major benefit.
Unlike pharmaceutical companies that will have to wait 3 to 5 years for clinical studies to wrap up and await FDA approval before ever seeing revenue...They might be able to drive revenue long before that point if they make sales directly to these research organizations.
According to reports, they've already developed partnerships with a leading veterans' organization in Canada for Phase 1 pre-clinical research. That could set Havn Life up to develop creative new formulations to potentially help treat veterans with PTSD and other trauma-related disorders.
The U.S. military has already spent $14 million to study the effects of psilocybin on posttraumatic stress disorder (PTSD) in veterans. So with tens of millions of dollars being spent by government agencies, Havn Life might have spotted an incredible opportunity. This is a huge accomplishment that could put them alongside Big Pharma giants like Johnson & Johnson and Abbvie, along with other billion-dollar companies in this growing space.
Standing Out from the Competition
With millions of people suffering from mental health conditions, Big Pharma has a serious problem. Despite these conditions having a devastating effect on these people's lives, many have made clear they have no interest in taking the lab-made medications Big Pharma is peddling.
With Havn Life (HAVN; HAVLF) committed to providing naturally derived mushroom extracts, this could give them a clear leg up against other suppliers making their products under microscopes in the labs.
They're reported to be the first company to be granted a Section 56 exemption from Health Canada, allowing them to work with psilocybin in a lab. And this important announcement has given them a necessary ingredient to start building protocols for their proposed GMP-compliant facility.
Revenue Potential Within Reach
Havn Life recently announced they have established a team on the ground in Jamaica, helping build up the lab where they can legally grow mushrooms and do extractions on-site. With this announcement, they've checked off another major box and become that much closer to becoming a supplier in this growing corner of the biotech market.
Havn Life says it already received their first research license from Health Canada last year, which gives them the thumbs up to research and develop psychedelic compounds. It looks like all they need to get started now is to secure their dealer's license, allowing them to supply and sell regulated compounds.
Other players in this market are sitting on multi-million and billion-dollar market caps as this industry takes off. MindMed boasts a market cap of $737 million. And Compass Therapeutics is currently valued at a market cap of $2.4 billion. But at the moment, Havn Life (HAVN; HAVLF) sits at around $60 million.
Psychedelics Could Be Bigger Than The Cannabis Boom
Tilray Inc. (TLRY) is one of Canada's most established and profitable marijuana companies. And as President-Elect Joe Biden continues to pursue efforts to legalize marijuana, and a new string of localized marijuana legalization hits the United States, investors are watching established giants like Tilray closely into the next stage of the cannabis boom.
While Tilray's share price took a hit in March of 2020 due to the ongoing COVID-19 pandemic, its recent earnings reports were significantly less disappointing than many analysts had expected. Thanks to this, Tilray has seen a bit of a turnaround, with its share price rising to a high of $29 in early 2021 before settling at today's levels.
Cronos Group (CRON) is another cannabis giant that took a hit during the first half of 2020. Since then, however, it has made a significant comeback, recapturing investor interest thanks to renewed sector-wide optimism. The bounce back in investor sentiment has also been reflected in its share price. In early 2021, Cronos saw its share price soar to $15 on the Biden-legalization hype, but it has settled down since.
Despite being primarily an equity investor, Cronos has also been making some major moves in its dealmaking in recent years, locking in agreements with some of the hottest names in the cannabis sector. Because of its ambitious plans and history of success, it has drawn the attention of some of the world's most influential companies, including the company behind Marlboro, Big Tobacco megalith Altria Group, which purchased a 45% stake in the company in 2018 for a total of $2.4 billion.
As the world's third-largest marijuana company, Aphria Inc (APHA), an Ontario-based marijuana giant currently has operations in 10 countries and distributes legal medical marijuana across the planet. And thanks to its unique approach to this emerging market, Aphria has proven itself to be resilient even amidst the global pandemic that has left many of its peers hurting.
One way Aphria has set itself apart in this turbulent market is through its acquisition of SweetWater Brewing, one of America's largest craft breweries. Aphiria's big gamble on SweetWater is an integral part of its big picture plan to capitalize on the booming 'lifestyle' market. A market that has grown in popularity through the rise of craft beers and specialized marijuana blends.
Aurora Cannabis (ACB) is another giant in Canada's cannabis scene. It's a veteran in the market, and as such, Aurora has been able to close a number of high-profile deals, including the acquisitions of CanniMed and MedReleaf. But that was just the beginning of its aggressive expansion strategy.
In November of 2020, Aurora announced a massive deal to supply marijuana to Cantek, a leader in Israel's booming medical market. The landmark deal would include deliveries totalling to a minimum of 4,000 kgs of bulk dried flower every year. "This Agreement provides Aurora with a great opportunity to expand our medical cannabis brand and industry leading science in one of our key international markets of focus," explained Miguel Martin, CEO of Aurora.
Canopy Growth Corporation (CGC) is a solid buy in the cannabis industry thanks to its massive partnerships. In fact, just this last year, beverage giant Constellation doubled down on the promising cannabis company once again, investing another $174 million into Canopy, raising its stake to 55.8%.
Canopy hasn't stopped there, however. In addition to its ties to the world's most influential adult-beverage brand, Canopy is also rubbing shoulders with celebs. In September of 2020, Canopy even teamed up with Martha Stewart to launch a new brand of CBD edibles in a variety of flavors.
By. Nick Cromwell
DGTrader55
4 years ago
HUGE NEWS
Havn Life Sciences hits major milestone with research partner,
Complex Biotech Discovery Ventures
Havn Research signs contract with CBDV, located at The University of British Columbia’s Vancouver
campus, to begin Health Canada approved research to analyze psilocybin under Havn Life’s
Section 56 exemption.
The results of the analysis will allow Havn Life to begin the development of a library of psilocybin
compounds.
December 16, 2020
Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP) (the “Company” or “Havn
Life”), a biotechnology company pursuing standardized extraction of psychoactive
compounds, the development of natural healthcare products, and innovative mental health
treatment to support brain health and enhance the capabilities of the mind, is pleased to
announce it is partnering with Complex Biotech Discovery Ventures (CBDV) to begin Health
Canada approved analysis of psilocybin under Havn Life’s section 56 exemption.
CBDV is a licensed cannabis research and development firm focusing on extraction,
optimization, analytical testing and chemical process development based at the Vancouver
Campus at the University of British Columbia.
Havn Life will be conducting a comparative study at CBDV lab that will test various
methodologies of extraction to assess the merits and drawbacks of each. The results will be
used to help develop Havn Life’s methodology for analyzing psilocybin mushrooms and
products.
In addition, Havn Life will work towards the development of the very first library of psilocybin
compounds and lay the foundation for future development of proprietary extraction methods.
“Analysis is the foundation of Havn Life’s research objectives, enabling quality assurance and
rapid development of our extraction techniques and methodologies,” says Alexzander
Samuelsson, Chief Research Officer for Havn Life. “By building a foundational understanding
of current methods used today, we will leverage known research to develop an optimal process
for the standardization of psilocybin extraction. This ultimately allows Havn to supply academic
researchers with high quality, standardized compounds.”
The study will provide Havn Life with the tools and an understanding of method development
for specific compounds (psilocybin) that can later be used to develop a library of compounds
for researchers.
“It will also mean that Havn Life can rapidly develop our proprietary extraction methods in?house more quickly by eliminating the need to send compounds to third-party labs,” explains Samuelsson. “This makes a huge difference between discovery and optimization to scaling
processes, allowing Havn Life to expedite our internal development process.”
The work is enabled by Havn Life’s Section 56 exemption, granted by Health Canada, pursuant
to which the company has the ability to possess certain amounts of pure psilocybin for scientific
purposes, specifically for the research and development of quality control methods.
The Section 56 exemption also provides Havn Life with unique access to handle psilocybin and
develop in-house analytical protocols. This will provide experience in quantitatively analyzing
psilocybin as a cornerstone of quality control and quality assurance for process development
and product reliability
https://webfiles.thecse.com/Havn_NR_-_Dec_15_-_CBDV.pdf?vX7_Bn75CFlpXX7uw0vFmQXQB0ue6DXx
DGTrader55
4 years ago
Havn Life Sciences Undertakes One of the First Preclinical Studies on Psilocybin and the Immune System
December 14, 2020, 6:00 am
This is one of the first studies to examine how psilocybin affects the immune system and is a required step to file an application with the Food and Drug Administration (FDA), for a Phase 1 clinical study in humans
VANCOUVER, BC / ACCESSWIRE / December 14, 2020 / Havn Life Sciences Inc. (CSE:HAVN) (FSE:5NP) (the "Company" or "Havn Life"), a Canadian biotechnology company pursuing standardized extraction of psychoactive compounds, the development of natural healthcare products, is pleased to announce the first preclinical study to focus on the effects of psilocybin on the immune system, in partnership with Dr. Geoffrey Bove, Dr. David Mokler and Susan Chapelle, eMBA.
The Company's science division, Havn Research, is undertaking a study to determine if a single dose of psilocybin extract can impact the body's inflammatory response and regulate the human immune system.
The Havn Life team will begin this preclinical study in Q1 2021. This study is the first step required to file an application for the development of psilocybin delivery methods that could address inflammatory and immune diseases such as arthritis.
Vic Neufeld, Executive Chairman of Havn Life stated: "We are tremendously excited about the potential to accelerate drug discovery and patient access to psilocybin based compounds. Upon completion of this initial phase, the Havn Life team will have taken the first step on its journey towards market authorization of new medicines. We intend to pursue the filing of an FDA application for psilocybin-based delivery methods, which may ultimately lead to new drug discovery. To date, minimal research has been done on psilocybin and its effects on human immunity, which is an area that has become more and more important."
Although there is discussion related to the possible effects of psilocybin on inflammation, there has been no research on psilocybin's impact on the immune system. This will be the one of the first studies to quantify the effects of psilocybin on the immune system and will also compare the differences in how psilocybin affects the immune system between the sexes.
"This is an exciting new application for psilocybin that has not yet been researched. The work is essential to understanding the safety profile of psilocybin and developing medicines to help support human health," says Susan Chapelle. "The findings could lead to significant discoveries in the treatments of inflammatory diseases that have a profound negative effect on so many, such as pain, neuropathy and arthritis."
About the Study
The Havn Life study will be conducted in the United States at Dr. Bove's biomedical centre, in Maine.
The principal researchers will be Doctor Geoffrey Bove, Doctor David Mokler, and Susan Chapelle, EVP of Research and Development at Havn Life, who each have extensive clinical experience in wound healing, pain receptors, psychedelic and pharmacology research. They jointly published a research paper on post-operative adhesions in 2017. The study findings laid the groundwork for further research on mechanical and pharmacologic approaches for post-operative.
Doctor Mokler, is an advisor for Havn Life and has a dual doctorate Pharmacology/Toxicology and Neurosciences from Michigan State University. His research, funded by the National Institute of Mental Health, focuses on the limbic (emotion/behavior) system of the brain, and the role of serotonin in the limbic system.
Susan Chapelle, eMBA is an expert in wound healing and has co-authored 6 publications in peer reviewed journals. She is a noted international Keynote Speaker and industry expert on research, science education, urban transformation, cannabis and psychedelics policy, and technology integrations.
Geoffrey Bove, DC PhD is a career neurobiologist and chiropractor who researches pain mechanisms, especially as related to physical diagnosis and manual therapies. He has been independently funded by the National Institutes of Health and other institutions for 30 years. Previously faculty at Harvard Medical School, Dr. Bove conducts research at his private laboratory, Bove Consulting
News
Market Data
Register for real-time alerts, custom portfolio, and market movers
Ask ADVFN Intelligence (AI)
Renee
2 years ago
Emerging Growth Conf
3 years ago
ListenToMe
3 years ago
Bulls on Parade
4 years ago
r1aviator
4 years ago
futrcash
4 years ago
ali g
4 years ago
TrendTrade2016
4 years ago
